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Sustainable synthesis of enantiopure ﬂuorolactam
derivatives by a selective direct ﬂuorination –
amidase strategy†
Nicky J. Willis,a Craig A. Fisher,b Catherine M. Alder,a Antal Harsanyi,b Lena Shukla,*a
Joseph P. Adamsa and Graham Sandford*b
Pharmaceutically important chiral ﬂuorolactam derivatives bearing a ﬂuorine atom at a stereogenic centre
were synthesized by a route involving copper catalyzed selective direct ﬂuorination using ﬂuorine gas for
the construction of the key C–F bond and a biochemical amidase process for the crucial asymmetric
cyclisation stage. A comparison of process green metrics with reported palladium catalyzed enantio-
selective ﬂuorination methodology shows the ﬂuorination-amidase route to be very eﬃcient and more
suitable for scale-up.
Introduction
Enzyme catalysed reaction of functional fluoromalonate build-
ing blocks, prepared using fluorine gas, has been used for the
first time for the enantioselective synthesis of a pharmaceuti-
cally important chiral fluorolactam derivative. An inexpensive,
highly economically competitive, lower waste stream process
that does not rely on precious metal catalysis and has been
quantified by green metric analysis is described.
The synthesis of chemical intermediates bearing a fluorine
atom at a stereogenic centre is becoming increasingly impor-
tant for applications across the materials and life-science
sectors.1 While fluoroaromatic derivatives appear as sub-units
in many commercially valuable pharmaceutical products,2
there are far fewer fluorinated drugs on the market where a
single fluorine atom is attached to an sp3 carbon, apart from
several anti-inflammatory fluorosteroid derivatives.3 One
reason for the relative lack of commercial products that bear
fluorine at a stereogenic centre is the often very diﬃcult syn-
thesis, but much progress in the field of enantioselective
chemical fluorination has been made in recent years.4 Fluori-
nation of positions α to a carbonyl group by an electrophilic
fluorination process is a common approach to the synthesis of
enantiopure fluorinated systems and various Selectfluor™-
cinchona alkaloid combinations,5 palladium or zinc catalysed
processes using N-fluorobenzenesulfonamide (NFSI),6 organo-
catalyst-fluorinating agent combinations7 and chiral fluorinat-
ing agents based upon Selectfluor™-type derivatives8 have
been devised and successfully implemented to give a range of
enantiopure fluorinated building blocks (Scheme 1). Whilst
these chemical approaches can be very valuable at the discov-
Scheme 1 Examples of reagent combinations used for the synthesis of
enantiopure systems with ﬂuorine located at a stereogenic centre.
†Electronic supplementary information (ESI) available: For experimental details
(SI-1), metrics calculations (SI-2), HPLC analysis (SI-3), X-ray crystallography
(SI-4) and NMR spectra (SI-5). CCDC 1401917-1401922. For ESI and crystallo-
graphic data in CIF or other electronic format see DOI: 10.1039/c5gc02209f
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ery stage of a medicinal chemistry process, the application of
chemical enantioselective fluorination strategies at larger scale
is severely hampered by the usually prohibitive expense of the
reagent-ligand combinations and the large waste streams
generated.
Pharmaceutical companies are increasingly concerned
about the environmental impact of their commercial products
and, for example, GSK recently announced an environmental
strategy with the objective that the company’s operations
become carbon neutral by 2050.9a Additionally, the European
Federation of Pharmaceutical Industries and Associations
(EFPIA) continues to develop the Eco-Pharmaco-Stewardship
(EPS) proposal to develop methods to minimise the eﬀect of
pharmaceuticals within the environment including in the
development and manufacturing stages.9b
Consequently, highly eﬃcient low-waste synthetic processes
for pharmaceutical manufacture are required to meet the
industry’s ambitious environmental goals. Therefore, methods
for assessing the eﬃciency and amount of waste generated by
a synthetic strategy are used, in part, to identify a suitable final
process for pharmaceutical manufacture. Green metrics
packages allow a holistic comparison between potential syn-
thetic reaction pathways using a mixture of quantitative and
qualitiative assessment criteria.10 Calculations of total process
mass intensity (PMI) enables the synthetic chemist to simply
compare the environmental eﬀect of competing synthetic
strategies from common starting materials, thus aiding the
selection of the final preparative route.11
A series of pre-clinical candidate spleen tyrosine kinase
(Syk) inhibitors12 1 have been synthesised from chiral fluoro-
lactam building blocks 2 (Scheme 2). General synthetic pro-
cedures for the preparation of enantiopure 2-fluoro-1,3-
amidoesters are relatively rare13 and are limited to enantio-
selective fluorination of malonate esters using NFSI with
Zn(OAc)2/DBFOX-Ph catalyst followed by amide formation,
6c
ligand catalysed chiral alkylation of fluoromalonate derivatives
followed by amide formation14 or fluorination using NFSI with
chiral palladium catalysis.12,15
The NFSI–palladium catalysis protocol reported by
Sodeoka15 was adopted for scale up and 2a was synthesised on
100 g scale12 (Scheme 3). However, the route12a,15 requires a
structurally complex palladium catalyst prepared by multi-step
procedures and purification of the desired enantiomer by
time-consuming chiral HPLC due to the relatively low 44% ee
obtained for the fluorination stage when performed on the
large scale.
Results and discussion
Our assessment of the reported synthesis of 2 (Scheme 3)
using green metric analysis (SI-2†), shows that the single-step
enantioselective fluorination reaction has an estimated calcu-
lated process mass intensity (PMI) value of 925 (SI-2†). Inspec-
tion of each stage of the synthetic route shows that most waste
is generated in the key enantioselective fluorination stage
because, of course, NFSI is synthesised by reaction of the
corresponding sulfonamide with fluorine gas,16 which must be
taken into account when calculating PMI measurements, and
loss of material due to the low ee and subsequent resolution.
We assumed that all solvent used in the HPLC resolution was
recycled and the waste generated in the multi-step synthesis of
the palladium catalyst was not included in the PMI calculation.
Consequently, the PMI 925 is a low estimate and oﬀers a
reasonable benchmark for process development.
As an alternative synthetic strategy, initially we investigated
the synthesis of related fluorolactam derivative 2b (R = Me)
using a combined chemical and biochemical synthetic
approach from fluoromalonate ester starting materials
(Scheme 2). While enzyme catalysed asymmetric hydrolysis of
various fluoromalonate derivatives have been developed,17 no
asymmetric amidase reactions of fluoromalonate derivatives
have been reported.Scheme 2 Retrosynthetic approach to Syk inhibitors 1.12
Scheme 3 Process mass intensity (PMI), mass intensity (MI), atom
economy (AE) and reaction mass eﬃciency (RME) calculations for the lit-
erature synthesis of 2a.
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Fluoromalonate ester 4a is synthesised in the high yield
direct fluorination reaction of dimethyl malonate ester using
fluorine gas catalysed by copper nitrate in acetonitrile solu-
tion.18a Recently, we described the optimisation of this process
which is routinely carried out on the 50 g scale and assessed
to have a mass intensity MI = 9 (Scheme 4).18b
Initial unoptimised synthesis of a range of racemic mono-
fluorinated functional precursors 4 for subsequent enzymatic
transformation reactions were carried out. Michael addition of
acrylonitrile19 to fluoromalonate 4a gave the desired nitrile 4b
in 90% yield and subsequent reduction of the nitrile group of
4b by hydrogen over palladium enabled the isolation of salt 4c.
Base catalysed ring closure gave racemic fluorolactam 4d
(Scheme 4, SI-1.2†). With products 4b–d in hand we began
attempts to resolve each fluorinated intermediate by appro-
priate enzymatic methods to identify the most eﬀective syn-
thetic sequence for the large scale synthesis of the desired
enantiopure chiral fluorolactam 2b.
Initially, hydrolase catalysed resolution of 4b was attempted
adapting literature protocols.20 However, nitrile 4b was
unstable in mildly basic aqueous media (pH 7.0–7.1) and so
this approach was discounted as a viable starting material for
desymmetrisation (SI-1.3†).
Attempted hydrolase promoted amidation in anhydrous
tertiary amyl alcohol as the solvent21 gave only racemic
product 4d from salt 4c using various enzyme catalysts
(SI-1.4†). After determining that 4d does not hydrolyse in
aqueous phosphate buﬀer (pH 7.3) to the corresponding acid
at 20–25 °C over 16 hours (SI-1.4†), enzymatic transformations
of 4c were explored in this aqueous buﬀered medium and,
indeed, 4d could be resolved by a variety of hydrolases. Follow-
ing an initial screening process of 56 enzymes (SI-1.5†), 25
promising hydrolases that aﬀorded 10–60% hydrolysis of 4d in
8 hours were analysed further (SI-1.5†). A number of highly
enantioselective processes were observed (Table 1) giving both
acids 5a,b by hydrolysis (SI-1.6†) and the corresponding esters
2b,c as reaction products. Both 2b and 2c were isolated by pre-
parative scale HPLC (SI-3†) and their structures and absolute
stereochemistries confirmed by X-ray crystallography (Fig. 1,
SI-4†).
CAL-B 10 000 is a recombinant Candida Antartica Lipase B
that is commercially available from Fermase and used to cata-
lyse a range of biotransformations on the large scale.22 Since
inexpensive CAL-B 10 000 aﬀords the desired fluorolactam
(S)-2b (entry 4, Table 1), and is available for purchase on the
multi-kilogram and tonne scale, this hydrolase was selected
for further reaction optimisation. The possibility of telescoping
the formation and resolution of 2b from salt 4c was explored
to reduce the work-up process. Initially when 4c was added to
buﬀer solution at room temperature to form a 25 mM solution,
we observed that the pH reduced from 7.3 to 6.7 after
15 minutes and that no side-reactions or degradation could be
detected. However, when the pH of the solution was readjusted
to 7.3 by addition of 2 N NaOH (0.92 equiv.), 19F NMR spectro-
scopic and chiral HPLC (SI-3†) analysis of the crude reaction
Table 1 Initial hydrolase resolution screening of 4d
Entry Hydrolase Conv. %a
Acid 5 Ester 2
ee % ee %
1 JM X14 30 >95 (S)-5a 62 (R)-2c
2 JM X35 19 >95 (S)-5a 19 (R)-2c
3 JM X50 28 >95 (S)-5a 37 (R)-2c
4 CAL-B 10 000 51 >95 (R)-5b >95 (S)-2b
a Calibrated UPLC-MS conversion.
Fig. 1 Molecular structures of (S)-2b (above) and (R)-2c (below).
Scheme 4 Initial unoptimised synthesis of racemic 4a–d.
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mixture indicated full conversion to the desired enantiopure
lactam 2b in 47% yield and 98% ee (Scheme 5, SI-1.7†).
The most operationally simple experimental protocol for
the transformation of 4c to 2b would be to add 4c in one
portion to the reaction mixture and then adjust the pH to 7.3.
Unfortunately, at 250 mM concentrations, the solution became
too acidic (pH 4.9) and hydrolysis by-products were formed.
This issue was, however, resolved by slow addition of the salt
and base, such that the pH was maintained between 6.8 and
7.3. Consequently, the desymmetrization reaction could be
telescoped very successfully at 257 mM concentration and the
desired fluorolactam 2b was separated eﬃciently by solid
phase extraction. CAL-B enzyme was recovered quantitatively
and recycled three times without any observed loss of reactivity
profile in subsequent cyclisation processes.
With basic operational parameters for the synthesis of
enantiopure 2b using inexpensive reagents and solvents in
place, we carried out studies to optimise the multistep
synthesis in order to assess the green metrics of the chemo-
enzymatic process in comparison to the published enantio-
selective fluorination strategy (Scheme 6).
In order to reduce the solvent use in reaction work-up, the
possibility of carrying out the subsequent Michael addition
reaction of 4a with acrylonitrile in a one-pot process without
any work-up after the fluorination stage was explored. Firstly,
the Michael addition reaction between the crude direct fluori-
nation product mixture and acrylonitrile was assessed but no
alkylation reaction occurred due to problems associated with
the presence of copper nitrate and HF in the reaction mixture.
Consequently, reactions in which a short series of environment-
ally benign bases including DBU, potassium phosphate and
2-methyl pyridine, were added to the crude direct fluorination
product mixture were screened. Addition of 0.5 equivalents of
potassium phosphate to the reaction mixture allowed the
Michael reaction to proceed to full conversion at room temp-
erature. Scale-up of the one-pot process on 100 mmol scale,
where the acrylonitrile was added to the crude direct fluorina-
tion reaction mixture via syringe pump over 30 minutes, gave
4b in 60% yield after 1.5 hours.
Reduction of the nitrile group of 4b was carried out in a
Parr hydrogenator with palladium/carbon in methanol and
conc. hydrochloric acid. Upon completion of the hydrogen-
ation, a white precipitate formed upon washing the crude reac-
tion mixture with ethanol which allowed simple filtration of
the ammonium hydrochloride salt 4c. After process optimi-
sation, the solvent volume used for the reduction could be
reduced significantly, providing 4c in 84% yield after recrystal-
lisation. The telescoped cyclisation and resolution process was
carried out on 10 g scale to obtain realistic metrics data, gener-
ating 2b in 43% isolated yield, 99% ee from 4c (Scheme 6,
SI-1.9–11†).
The three stage, enhanced synthesis of (S)-2b from dimethyl
malonate ester gave a calculated PMI = 201, over four times
lower than the corresponding enantioselective chemical syn-
thesis strategy used previously.15
Experimental
Optimised synthesis of 2b (Scheme 6)
Telescoped fluorination-Michael addition: synthesis of
dimethyl (2-cyanoethyl)-2-fluoromalonate 4b. Dimethyl malo-
nate 4a (26.40 g, 200 mmol) and copper(II) nitrate hemi(penta-
hydrate) (4.65 g, 20 mmol) were dissolved in acetonitrile
(100 mL) and the mixture was cooled to 0–5 °C and stirred at
650 rpm using an overhead stirrer. After purging the system
with N2 for 5 minutes, fluorine gas (20% v/v in N2, 100 mL
min−1, 220 mmol) was introduced into the reaction mixture
for 4 h 25 min. After purging with nitrogen for 5 min, potass-
ium phosphate tribasic (anhydrous) (42.45 g, 200 mmol) was
added to the reaction mixture and stirred. After 1 h the potass-
ium phosphate was removed by filtration and washed with
acetonitrile (2 × 20 mL) before a further portion of potassium
phosphate (42.45 g, 200 mmol) was added to the solution
which was heated to 55 °C. Acrylonitrile (12.73 g, 240 mmol)
in acetonitrile (10 mL) was added over 30 min and the solution
stirred. After a further 3.25 h the potassium phosphate was
removed by filtration and washed with acetonitrile (3 × 20 mL)
and the filtrate was concentrated in vacuo. Vacuum distillation
(140–141 °C, 6 mbar) of the crude product yielded dimethyl(2-
cyanoethyl)-2-fluoromalonate 4b (24.45 g, 60%) as a clear oil;
([MH]+, 204.0652. C8H11FNO4 requires: [MH]
+, 204.0672); IR
(neat, cm−1) 2962, 2253, 1748, 1438; 1H NMR (400 MHz,
CDCl3) δ 3.85 (6H, s, OCH3), 2.60–2.49 (4H, m, CH2);
19F NMR
(376 MHz, CDCl3) δ −167.85–−168.04 (m); 13C NMR (101 MHz,
CDCl3) δ 165.42 (d,
2JCF 25.3, CvO), 117.88 (s, CN), 92.73 (d,
1JCF 201.0, C–F), 53.86 (s, CH3O), 30.16 (d,
2JCF 21.5, CH2),
11.48 (d, 3JCF 5.5, CH2); m/z (ASAP) 204.1 (100%, [MH]
+),
162.1 (25).
Scheme 6 Optimised synthesis of 2b.
Scheme 5 Synthesis of ﬂuorolactam 6 from 4c.
Paper Green Chemistry
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Reduction: synthesis of dimethyl 2-(3-aminopropyl)-2-fluoro-
malonate, hydrochloride salt 4c. 10% Pd/C (2.62 g, 5 mol%)
and conc. HCl (4.85 mL) were added into a Hastelloy autoclave.
A solution of dimethyl(2-cyanoethyl)-2-fluoromalonate 4b (10 g,
49.2 mmol) in methanol (43.3 mL) was added and the vessel
sealed. The vessel was pressurized with H2 (4 bar) and the con-
tents were stirred at 600 rpm. After 16 h the solution was
filtered through celite (2 g) with methanol (20 mL) and evapor-
ated to give crude 4c. The solid was washed with methanol (2 ×
20 mL) and acetone (2 × 15 mL) to give dimethyl2-(3-amino-
propyl)-2-fluoromalonate, hydrochloride salt 4c (10.43 g, 84%) as
white crystals; mp 147–148 °C; ([M − Cl]+, 208.0978.
C8H15FNO4 requires [M − Cl]+, 208.0985); IR (neat, cm−1) 3016,
2942, 1748, 1580, 1437, 1249, 1033; 1H NMR (400 MHz, metha-
nol-d4) δ 3.87 (6H, s, OCH3), 3.08–2.98 (2H, m, CH2), 2.32 (2H,
ddd, 3JHF 23.1,
3JHH 9.2,
3JHH 6.9, CH2), 1.89–1.77 (2H, m,
CH2);
19F NMR (376 MHz, methanol-d4) δ −167.20 (t, 3JHF
23.1); 13C NMR (101 MHz, methanol-d4) δ 167.60 (d,
2JCF 25.8,
CvO), 95.57 (d, 1JCF 197.4, C–F), 54.10 (s, CH3O), 40.21 (s,
CH2NH2), 32.18 (d,
2JCF 21.6, CH2CF), 22.38 (d,
3JCF 3.2, CH2);
m/z (ASAP) 208.1 (100%, [M − Cl]+), 191 (14), 176 (8).
Cyclization: synthesis of (S)-methyl 3-fluoro-2-oxopiperidine-
3-carboxylate 2b. To a 500 mL round bottomed flask was
added 0.06 M Na2HPO4: 0.06 M KH2PO4 buﬀer (164 mL, 3 : 1,
pH 7.3) followed by 4c (10.00 g, 41.0 mmol) in small portions
using 0.5 M NaOH to buﬀer the solution to pH 7.3. The solu-
tion was filled to 328 mL total volume with further 0.06 M
Na2HPO4: 0.06 M KH2PO4 buﬀer (3 : 1, pH 7.3) to give a
257 mM solution Fermase immobilised CAL-B 10 000 (7.2 g)
was added to the reaction mixture which was stirred at 100
rpm at 20 °C for 8 h. The reaction mixture was poured onto a
Waters Oasis HLB 12cc 5 g LP extraction cartridge under
reduced pressure and water (30 mL) was added to the cartridge
such that the acid was fully eluted (ca. 1 mL per min). The
washed enzyme was removed and the ester was eluted with
20% formic acid (30 mL). The solution was concentrated
under reduced pressure at RT to give a solid, which was recrys-
tallised from acetone (10 mL) to give (S)-methyl 3-fluoro-2-oxo-
piperidine-3-carboxylate 2b (3.15 g, 44%, >99% ee) as white
crystals; mp 115–116 °C; [α]D +14.393° (c 1.00, MeCN); ([MH]
+,
176.0718. C7H11FNO3 requires: [MH]
+, 176.0723); IR (neat,
cm−1) 3200, 3074, 2968, 2888, 1760, 1668, 1435; 1H NMR
(400 MHz, CDCl3) δ 7.49 (1H, s, NH), 3.85 (3H, s, OCH3),
3.45–3.37 (2H, m, CH2), 2.42–2.20 (2H, m, CH2), 2.04–1.89 (2H,
m, CH2);
19F NMR (376 MHz, CDCl3) δ −156.07 (dd, 3JHF 28.2,
3JHF 20.0);
13C NMR (101 MHz, CDCl3) δ 168.68 (d,
2JCF 26.2,
NH–CvO), 165.13 (d, 2JCF 22.4, CO2), 90.87 (d,
1JCF 190.8, C–F),
53.29 (s, CH3O), 42.22 (s, CH2–NH), 31.25 (d,
2JCF 22.4, CH2–
CF), 18.26 (d, 3JCF 2.6, CH2); m/z (ASAP) 176 (100%, [MH]
+), 162 (9).
Conclusions
In conclusion, the combined three stage chemo-enzymatic syn-
thesis of enantiopure fluorolactam 2b using fluorine gas for
the construction of the C–F bond and amidase CAL-B 10 000
for the key desymmetrization step has been optimised on a
reasonable scale and is suitable for scale-up. The PMI of the
fluorination-amidase route is PMI = 201 compared to PMI =
925 for the enantioselective fluorination literature synthesis.
Clearly, the fluorination-amidase route established here has a
PMI that is highly competitive with the corresponding chemi-
cal synthesis and demonstrates the very eﬀective use of
amidase enzymes for larger scale synthesis of challenging
pharmaceutically relevant enantiopure fluorinated systems.
However, the still relatively high PMI for the three step syn-
thetic process is largely due to the final resolution step which,
by definition, leads to the loss of half the product material.
Perhaps of more importance for synthesis on the large scale
is that the cost of the overall fluorination-amidase process is
several orders of magnitude less expensive than the use of
enantioselective fluorination strategies that require the utilis-
ation of relatively expensive N–F electrophilic fluorinating
agents prepared from fluorine gas and the use of structurally
complex precious metal catalysts. Simple recycling of the
enzyme catalyst by filtration, recycling of solvents and a high
yielding inexpensive, copper catalysed fluorination step make
the strategy very attractive for scale-up.
The use of the fluorine-enzyme multi-step approach comp-
lements existing chemical enantioselective fluorination pro-
cedures that are more applicable to discovery scale synthesis.
Here, we have demonstrated that the development of new
fluorinated sub-units within drug structures bearing fluorine
at a chiral sp3 centre assessed in the discovery phase by chemi-
cal enantioselective fluorination on the small scale can, when
required, be scaled up by a combined inexpensive fluorination-
enzyme catalysed approach thus extending the chemical space
for fluorinated aliphatic units within the structures of drug
candidates.
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